secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001437749-24-034557
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma Q3 product sales +40% YoY, first positive GAAP net income from product sales
--------------------------------------------------------------------------------

- Total revenue $10.3M, net income $0.6M ($0.02 diluted EPS); prior year net loss $0.6M.
- Product sales $9.8M, up 40% YoY and 8% sequentially; 15th straight quarter of sequential growth.
- Entered asset purchase agreement to acquire Increlex from Ipsen, expected to close near year-end 2024 and be accretive to 2025 earnings.
- FDA accepted ET-400 NDA with PDUFA date Feb 28, 2025; additional patent granted for ET-400 expiring 2043.
- Cash $20.3M; generated $2.9M operating cash flow in Q3; expects positive Q4 cash flow and will fund Increlex with cash on hand and credit facility expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924034557/0001437749-24-034557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924034557/eton20240930c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-034557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer